572 related articles for article (PubMed ID: 28989060)
1. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
[TBL] [Abstract][Full Text] [Related]
2. Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease.
Mahmud N; Shaked A; Olthoff KM; Goldberg DS
Liver Transpl; 2019 Mar; 25(3):388-398. PubMed ID: 30362249
[TBL] [Abstract][Full Text] [Related]
3. Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-centre experience.
Wehrle CJ; Raj R; Maspero M; Satish S; Eghtesad B; Pita A; Kim J; Khalil M; Calderon E; Orabi D; Zervos B; Modaresi Esfeh J; Whitsett Linganna M; Diago-Uso T; Fujiki M; Quintini C; Kwon CD; Miller C; Pinna A; Aucejo F; Hashimoto K; Schlegel A
Int J Surg; 2024 May; 110(5):2818-2831. PubMed ID: 38241354
[TBL] [Abstract][Full Text] [Related]
4. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant.
Sarkar M; Dodge JL; Roberts JP; Terrault N; Yao F; Mehta N
Ann Hepatol; 2016; 15(4):545-9. PubMed ID: 27236153
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study.
Han SH; Reddy KR; Keeffe EB; Soldevila-Pico C; Gish R; Chung RT; Degertekin B; Lok A;
Clin Transplant; 2011; 25(2):E152-62. PubMed ID: 21077950
[TBL] [Abstract][Full Text] [Related]
6. Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era.
Mahmud N; Yagan L; Hoteit MA; Reddy KR; Abt PL; Abu-Gazala S
Transplantation; 2024 May; 108(5):1172-1178. PubMed ID: 37953481
[TBL] [Abstract][Full Text] [Related]
7. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma.
Tyson GL; Duan Z; Kramer JR; Davila JA; Richardson PA; El-Serag HB
Clin Gastroenterol Hepatol; 2011 Nov; 9(11):989-94. PubMed ID: 21820396
[TBL] [Abstract][Full Text] [Related]
8. Proposal for Prognosis-Oriented Definition of Borderline Resectable Hepatocellular Carcinoma.
Haruki K; Harimoto N; Furukawa K; Taniai T; Yanagaki M; Igarashi Y; Tsunematsu M; Shirai Y; Shirabe K; Ikegami T
J Am Coll Surg; 2024 Jun; 238(6):1137-1147. PubMed ID: 38323632
[TBL] [Abstract][Full Text] [Related]
9. Development of a machine learning-based model to predict prognosis of alpha-fetoprotein-positive hepatocellular carcinoma.
Dong B; Zhang H; Duan Y; Yao S; Chen Y; Zhang C
J Transl Med; 2024 May; 22(1):455. PubMed ID: 38741163
[TBL] [Abstract][Full Text] [Related]
10. "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China.
Lei JY; Wang WT; Yan LN
World J Gastroenterol; 2013 Nov; 19(44):8093-8. PubMed ID: 24307805
[TBL] [Abstract][Full Text] [Related]
11. The number of hepatocellular carcinoma foci as predictor of poor response to tumor-directed therapies in patients awaiting liver transplantation: a prospective cohort study.
Aydin Y; Koksal AR; Thevenot P; Nunez K; Elgamal M; Koksal UI; Sandow T; Moehlen M; Regenstein F; Tahan V; Cohen A
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1224-1229. PubMed ID: 37577793
[TBL] [Abstract][Full Text] [Related]
12. Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients.
Cucchetti A; Sposito C; Pinna AD; Citterio D; Cescon M; Bongini M; Ercolani G; Cotsoglou C; Maroni L; Mazzaferro V
World J Gastroenterol; 2017 Feb; 23(8):1469-1476. PubMed ID: 28293094
[TBL] [Abstract][Full Text] [Related]
13. Simple Risk Score for Prediction of Early Recurrence of Hepatocellular Carcinoma within the Milan Criteria after Orthotopic Liver Transplantation.
Feng J; Wu J; Zhu R; Feng D; Yu L; Zhang Y; Bu D; Li C; Zhou Y; Si L; Liu Y; Liang Z; Xu J; Wu T
Sci Rep; 2017 Mar; 7():44036. PubMed ID: 28276470
[TBL] [Abstract][Full Text] [Related]
14. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.
Toyoda H; Lai PB; O'Beirne J; Chong CC; Berhane S; Reeves H; Manas D; Fox RP; Yeo W; Mo F; Chan AW; Tada T; Iñarrairaegui M; Vogel A; Schweitzer N; Chan SL; Sangro B; Kumada T; Johnson PJ
Br J Cancer; 2016 Mar; 114(7):744-50. PubMed ID: 27022825
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.
Samoylova ML; Dodge JL; Mehta N; Yao FY; Roberts JP
Clin Transplant; 2015 Jan; 29(1):52-9. PubMed ID: 25366656
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of liver transplant candidates for hepatocellular carcinoma in a single center.
Ho CM; Lee PH; Cheng HY; Hsaio CY; Wu YM; Ho MC; Hu RH
Langenbecks Arch Surg; 2024 Apr; 409(1):143. PubMed ID: 38683375
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.
Zhang L; Liu P; Zhuang L; Ling S; Zhan Q; Zhou W; Su R; Yin L; Que Q; Hong J; Bao J; Shao C; Cai J; Zheng S; Xu X
Mol Biomed; 2024 Mar; 5(1):9. PubMed ID: 38461206
[TBL] [Abstract][Full Text] [Related]
18. Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score.
Hahn M; Herber A; Berg T; Seehofer D; van Bömmel F
J Hepatol; 2024 Jun; 80(6):e271-e272. PubMed ID: 38110004
[No Abstract] [Full Text] [Related]
19. A mathematical model for optimizing the indications of liver transplantation in patients with hepatocellular carcinoma.
Chaib E; Amaku M; Coutinho FA; Lopez LF; Burattini MN; D'Albuquerque LA; Massad E
Theor Biol Med Model; 2013 Oct; 10():60. PubMed ID: 24139285
[TBL] [Abstract][Full Text] [Related]
20. Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
Norman JS; Mehta N
J Hepatol; 2024 Jun; 80(6):e273-e274. PubMed ID: 38346579
[No Abstract] [Full Text] [Related]
[Next] [New Search]
